NDLI: Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

Please wait, while we are loading the content...

Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study.

Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.

Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.

Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.

Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers.

Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.

The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Update of the 2009 Italian Pediatric Society Guidelines about management of fever in children.

Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.

Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study.

Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

Year: 2012 Volume: 34 Issue: 6

Year: 2012 Volume: 34 Issue: 5

Year: 2012 Volume: 34 Issue: 4

Year: 2012 Volume: 34 Issue: 3

Year: 2012 Volume: 34 Issue: 2

Year: 2012 Volume: 34 Issue: 1

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chen, Jack J. Ondo, William G. Dashtipour, Khashayar Swope, David M.
Description	Country affiliation: United States Author Affiliation: Chen JJ ( Movement Disorders Clinic,Schools of Medicine and Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA. jjchen@llu.edu)
Abstract	BACKGROUND: Tetrabenazine (TBZ) is a monoamine storage inhibitor that was first introduced in the 1970s for the management of hyperkinetic movement disorders. Despite acceptance and usage worldwide, TBZ was only recently approved in the United States for the treatment of Huntington chorea. This review focuses on the use of TBZ in various hyperkinetic movement disorders, which are considered 'rare' or 'orphan' diseases, to help practitioners better understand its clinical role and use. OBJECTIVE: This review describes the clinical efficacy and tolerability of TBZ in the management of dystonia, Huntington chorea, tardive dyskinesia (TDk), and tic disorders. METHODS: A Cochrane Library, EMBASE, MedlinePlus, PubMed, and clinical trials database search (up to May 2012) was conducted to identify articles and studies using the subject terms tetrabenazine, Huntington disease, dystonia, tardive dyskinesia, Tourette, tics, and hyperkinetic movement. Only English-language articles were reviewed. RESULTS: TBZ variably undergoes extensive first-pass metabolism to active metabolites, some of which are metabolized by the cytochrome P450 2D6 isozyme. Pharmacology studies demonstrate that TBZ reversibly inhibits the activity of vesicular monoamine transporter 2, resulting in depletion of central dopamine. For management of dystonias, 1 of 3 small prospective blinded studies and 4 of 5 retrospective studies reported clinical benefit with TBZ use in pediatrics and adults. For Huntington chorea, 2 randomized, double-blind, placebo-controlled studies along with open-label studies demonstrate the effectiveness of TBZ in adults. For TDk, 9 of 11 studies (prospective controlled and retrospective) reported positive benefit. For Gilles de la Tourette syndrome, 9 of 11 studies (prospective controlled and retrospective) reported positive benefit on motor and phonic tics in pediatric and adult patients. Overall, adverse effects are dose and age related and include depression, fatigue, parkinsonism, and somnolence. CONCLUSIONS: TBZ is an effective oral therapy for chorea of Huntington disease and may be considered as an alternative agent for the management of dystonia, TDk, and tic disorders (these latter 3 conditions are off-label uses in the United States). The drug possesses an acceptable tolerability profile and has been used in pediatric and adult populations.
File Format	HTM / HTML
ISSN	01492918
Issue Number	7
Volume Number	34
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2012-07-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Adrenergic Uptake Inhibitors Therapeutic Use Hyperkinesis Drug Therapy Tetrabenazine Adverse Effects Pharmacology Animals Chorea Physiopathology Dystonia Humans Huntington Disease Movement Disorders Rare Diseases Tic Disorders Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.

The long-term effect of tetrabenazine in the management of Huntington disease.

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.

Treatment of hyperkinetic movement disorders.

Tetrabenazine for the treatment of tardive dyskinesia.

Tetrabenazine.

Role of tetrabenazine for Huntington's disease-associated chorea.

Treatment of involuntary movement disorders with tetrabenazine.

Sensory trick with metoclopramide-associated tardive tremor.

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

Similar Documents

Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.

The long-term effect of tetrabenazine in the management of Huntington disease.

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.

Treatment of hyperkinetic movement disorders.

Tetrabenazine for the treatment of tardive dyskinesia.

Tetrabenazine.

Role of tetrabenazine for Huntington's disease-associated chorea.

Treatment of involuntary movement disorders with tetrabenazine.

Sensory trick with metoclopramide-associated tardive tremor.

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.